MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

MDT

100.99

-0.45%↓

A

134.88

-2.69%↓

VEEV

221.76

-1.44%↓

HQY

84.14

-2.65%↓

NEOG

9.81

-1.21%↓

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

114.59 -2.34

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

113.22

Max

117.65

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+7.72% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-02-19

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

5.6B

15B

Ankstesnė atidarymo kaina

116.93

Ankstesnė uždarymo kaina

114.59

Naujienos nuotaikos

By Acuity

50%

50%

158 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-23 18:41; UTC

Uždarbis

SLB Readies Rapid Expansion in Venezuela -- 2nd Update

2026-01-23 22:30; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-23 22:30; UTC

Rinkos pokalbiai

Trump Seen Using Canada's EV Deal With China to Extract Concessions -- Market Talk

2026-01-23 22:03; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026-01-23 21:52; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

GE Aerospace's Earnings Worried the Market. What CEO Larry Culp Says. -- Barrons.com

2026-01-23 21:50; UTC

Rinkos pokalbiai
Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-01-23 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-01-23 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-23 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-23 21:39; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 5th Update

2026-01-23 21:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Ultra PCS Limited, Expanding Capabilities And Solutions For Next-generation Aerospace And Defense Markets >ETN

2026-01-23 21:12; UTC

Uždarbis

CSX Stock Rises After Earnings Miss Estimates. It's the Outlook. -- Barrons.com

2026-01-23 20:31; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, AMD, Capital One, Booz Allen, BitGo, Fortinet, and More -- Barrons.com

2026-01-23 20:12; UTC

Rinkos pokalbiai

Oil Futures Rebound on Iran, Russia-Ukraine Risk -- Market Talk

2026-01-23 20:07; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Record Weekly Gain on Winter Storm -- Market Talk

2026-01-23 19:36; UTC

Rinkos pokalbiai

Dollar Weakens Against Yen Amid Intervention Chatter -- Market Talk

2026-01-23 19:30; UTC

Rinkos pokalbiai
Uždarbis

Intel's Stock Has Limited Catalysts Ahead, Analysts Say -- Market Talk

2026-01-23 19:18; UTC

Rinkos pokalbiai

Gold and Silver Step Up to More Records -- Market Talk

2026-01-23 19:15; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 4th Update

2026-01-23 18:53; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises By 1 to 411 -- Market Talk

2026-01-23 18:21; UTC

Uždarbis

Week's Best: Schwab's Assets and Profits Keep Climbing -- Barrons.com

2026-01-23 18:19; UTC

Rinkos pokalbiai

Intel Seen as Increasingly Confident on Demand -- Market Talk

2026-01-23 17:59; UTC

Uždarbis

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- 3rd Update

2026-01-23 17:57; UTC

Rinkos pokalbiai

Intel Could Sign Deals With Big Tech Players for 14A -- Market Talk

2026-01-23 17:57; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-01-23 17:34; UTC

Rinkos pokalbiai
Uždarbis

Intel's Supply Challenges Seen Benefiting AMD -- Market Talk

2026-01-23 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-01-23 17:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-01-23 17:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-01-23 17:13; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

7.72% į viršų

12 mėnesių prognozė

Vidutinis 124.69 USD  7.72%

Aukščiausias 155 USD

Žemiausias 105 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

18

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

158 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat